Thyroid Cancer Diagnostics Market Size, Share & Trends Analysis Report By Cancer Type (Papillary Carcinoma, Follicular Carcinoma), By Technique (Imaging, Biopsy, Blood Test), By End-use, By Region, And Segment Forecasts, 2025 - 2030

Thyroid Cancer Diagnostics Market Trends

The global thyroid cancer diagnostics market size was valued at USD 3.07 billion in 2024 and is expected to grow at a CAGR of 5.3% from 2025 to 2030. This growth is attributed to the growing incidence of thyroid cancer, growing awareness of early screening programs, and significant technological advancements in diagnostic tools such as imaging modalities and molecular testing. In addition, increased healthcare spending, favorable reimbursement policies, and a shift toward personalized medicine. Furthermore, the growing aging population, improved healthcare infrastructure, and ongoing research and development efforts further support market expansion, enabling earlier and more accurate detection and management of thyroid cancer.

Thyroid cancer diagnostics encompass a broad range of tests and procedures, including imaging, biopsies, blood tests, and molecular profiling used to detect and characterize thyroid cancer, guiding clinical decisions and personalized treatment. The global market for these diagnostics is expanding rapidly, largely due to the increasing number of thyroid cancer patients. This rise in cases has heightened the demand for early detection and effective screening tools, as healthcare providers prioritize proactive identification to improve outcomes. According to the American Cancer Society, about 44,020 new cases of thyroid cancer are expected to be diagnosed in the U.S. in 2025. Approximately 31,350 cases occur in women and 12,670 in men. Thyroid cancer is notably more common in women and is often diagnosed at a younger age compared to many other cancers.

A significant driver of this market is technological advancement. For instance, in May 2024, GE Healthcare introduced Revolution RT, an advanced radiation therapy computed tomography (CT) solution. This innovative system is designed to enhance imaging accuracy and streamline simulation workflows, supporting a more personalized and seamless oncology care experience. Revolution RT incorporates AI-driven technologies and updated software platforms, enabling clinicians to achieve precise tumor targeting and more efficient care pathways.

In addition, the adoption of telemedicine and digital health platforms has further expanded access to thyroid cancer diagnostics, especially for individuals in remote or underserved areas. Through virtual consultations, patients can receive early screening recommendations and follow-up care, ensuring timely intervention regardless of geographic barriers.

Moreover, the growing prevalence of genetic testing for hereditary risk factors is creating new opportunities in the market. Advanced genomic panels can identify mutations linked to thyroid tumors, aiding in more accurate diagnosis and personalized treatment strategies. Collectively, these factors, including the rising incidence of thyroid cancer, cutting-edge technology like Revolution RT, the shift toward personalized medicine, digital health accessibility, and expanded genetic testing, are driving robust growth in the thyroid cancer diagnostics market, leading to earlier detection and improved patient care.

Cancer Type Insights

Papillary carcinoma led the market and accounted for the largest revenue share of 80.0% in 2024, primarily driven by its high prevalence, accounting for the majority of thyroid cancer cases globally. In addition, increased awareness, improved screening programs, and advancements in imaging and molecular diagnostic techniques have enabled earlier and more accurate detection. Furthermore, environmental factors, lifestyle changes, and a younger average age at diagnosis also contribute to rising case numbers, driving demand for effective diagnostic solutions and supporting market expansion for this cancer type.

Follicular carcinoma diagnostics is expected to grow at a CAGR of 5.6% over the forecast period, owing to its status as the second most common thyroid cancer, with a higher malignancy potential compared to papillary carcinoma. Furthermore, rapid invasion into surrounding tissues and a lower cure rate with increasing age highlight the need for precise and early detection. Moreover, increased susceptibility among females, greater focus on early diagnosis, and advancements in diagnostic technologies further fuel market growth for follicular carcinoma in the global thyroid cancer diagnostics segment.

Technique Insights

Imaging technique dominated the global thyroid cancer diagnostics market with the largest revenue share of 36.9% in 2024. This growth is attributed to its critical role in the early detection and evaluation of thyroid nodules and tumors. Furthermore, advanced imaging modalities such as ultrasound, CT, MRI, and PET scans provide non-invasive, highly accurate, and rapid results, improving diagnostic confidence. Moreover, the integration of artificial intelligence and enhanced imaging resolution further supports precise tumor localization and monitoring, making imaging an indispensable tool in thyroid cancer diagnosis and management.

Biopsy technique is expected to grow at a significant CAGR of 5.4% over the forecast period, owing to its essential function in confirming thyroid cancer diagnosis at the cellular level. In addition, the increasing adoption of molecular and genetic analysis through biopsy samples enables more personalized and targeted treatment strategies. Furthermore, advances in next-generation sequencing and biomarker analysis have improved diagnostic accuracy, supporting individualized care. The demand for minimally invasive, reliable, and definitive diagnostic techniques continues to drive the expansion of biopsy in the market.

End-use Insights

Hospital laboratories held the dominant position in the market and accounted for the largest revenue share of 37.4% in 2024, driven by increasing patient inflow for cancer diagnosis, rising awareness of thyroid disorders, and expanding healthcare infrastructure, especially in developing regions. In addition, hospitals are often the primary point of care, providing comprehensive diagnostic services, advanced technologies, and specialized personnel. Furthermore, investments in modern equipment and integration of molecular and genetic testing capabilities further enhance the accuracy and efficiency of thyroid cancer diagnostics in hospital settings, supporting continued market expansion.

Research institutes are expected to grow at a CAGR of 6.4% from 2025 to 2030, due to increased global funding for cancer research and a strong focus on innovation. These institutes play a pivotal role in developing and validating new diagnostic technologies, such as advanced molecular assays and genetic profiling. Furthermore, collaborative efforts with academic and industry partners, access to grant funding, and participation in clinical trials drive breakthroughs in early detection and personalized medicine, positioning research institutes as key contributors to market advancement.

Regional Insights

North America thyroid cancer diagnostics market dominated the global market with the largest revenue share of 40.2% in 2024. This growth is attributed to a high prevalence of thyroid cancer, robust healthcare infrastructure, and widespread adoption of advanced molecular diagnostic technologies. In addition, the region benefits from significant investments in research, favorable reimbursement policies, and active government initiatives promoting early detection. Furthermore, the presence of leading manufacturers and strong commercial performance also accelerates market growth, while ongoing awareness campaigns and access to innovative diagnostic solutions ensure continued expansion across the region.

U.S. Thyroid Cancer Diagnostics Market Trends

The thyroid cancer diagnostics market in the U.S. led the North American market with the largest revenue share in 2024, driven by a large patient pool, high healthcare spending, and rapid integration of genetic testing, AI-driven imaging, and biomarker research. The country’s focus on early detection is supported by public health campaigns and regulatory support for advanced diagnostic products. Furthermore, favorable insurance coverage, active research and development, and the presence of top-tier medical institutions contribute to the adoption of cutting-edge diagnostic technologies, making the U.S. a leader in thyroid cancer diagnostics.

Asia Pacific Thyroid Cancer Diagnostics Market Trends

Asia Pacific thyroid cancer diagnostics market is expected to grow at the fastest CAGR of 8.9% over the forecast period, owing to a rising incidence of thyroid cancer, increasing healthcare expenditure, and expanding diagnostic infrastructure. In addition, government initiatives to enhance cancer screening, growing consumer awareness, and the entry of major market players are key contributors. Furthermore, rapid urbanization, improved access to healthcare services, and advancements in imaging and molecular diagnostics are also driving demand, particularly in emerging economies within the region.

The thyroid cancer diagnostics market in Japan led the Asia Pacific market and held the largest revenue share in 2024. This is attributed to an aging population, high health consciousness, and strong governmental focus on cancer screening programs. Furthermore, the country’s advanced healthcare system supports the adoption of innovative diagnostic technologies. Moreover, increased investment in research, collaboration with global industry leaders, and public awareness campaigns have led to early detection and improved patient outcomes, making Japan a significant contributor to regional market expansion.

Europe Thyroid Cancer Diagnostics Market Trends

The European thyroid cancer diagnostics market is expected to witness significant growth over the forecast period, fueled by rising thyroid cancer incidence, supportive healthcare policies, and the integration of advanced diagnostic techniques. In addition, the region benefits from substantial funding for research, cross-border collaborations, and harmonized regulatory standards that streamline the introduction of new diagnostic products. Furthermore, public health initiatives, widespread access to healthcare, and the adoption of digital and molecular diagnostics contribute to improved detection rates and sustained market growth across European countries.

Key Thyroid Cancer Diagnostics Company Insights

Key players in the global thyroid cancer diagnostics market include F.Hoffmann-La Roche Ltd., Thermo Fisher Scientific, Inc., Siemens Healthcare GmbH, and others. These companies implement strategies such as investing in research and development, introducing advanced diagnostic technologies, expanding product portfolios, forming collaborations and partnerships, and focusing on regulatory approvals. These approaches help enhance diagnostic accuracy, broaden market reach, and address evolving patient and healthcare provider needs.

• Siemens Healthcare GmbH offers a comprehensive portfolio of laboratory assays and automated immunoassay systems designed to detect, diagnose, and monitor thyroid disorders, including thyroid cancer. The company manufactures and supplies advanced diagnostic solutions that are used to assess thyroid function, monitor differentiated thyroid cancer, and support clinical decision-making. Siemens operates primarily in the laboratory diagnostics and medical imaging segments.

• Bio-Rad Laboratories, Inc. develops and markets a wide range of molecular testing kits, reagents, and automated systems that enable the detection and analysis of thyroid cancer biomarkers. Bio-Rad operates in the clinical diagnostics segment, providing tools for genetic, protein, and cellular analysis. It supports both routine diagnostic testing and advanced research in thyroid cancer and related endocrine disorders.

Recent Developments

• In October 2024, GE HealthCare took a leading role in Thera4Care, an initiative to revolutionize cancer care through theranostics. This personalized approach integrates imaging diagnostics and targeted therapeutics, using molecular imaging to visualize tumors and deliver radioactive drugs.

• In August 2024, Illumina's TruSight Oncology (TSO) Comprehensive test secured FDA approval, marking a milestone as the pan-cancer companion diagnostic claims and the first distributable comprehensive genomic profiling IVD kit.

Thyroid Cancer Diagnostics Market Report Scope

Global Thyroid Cancer Diagnostics Market Report Segmentation

This report forecasts revenue growth at global, regional and country level and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global thyroid cancer diagnostics market report based on cancer type, technique, end-use, and region.

• Cancer Type Outlook (Revenue, USD Million, 2018 - 2030)

  • Papillary carcinoma

  • Follicular carcinoma

  • Others

• Technique Outlook (Revenue, USD Million, 2018 - 2030)

  • Blood Test

  • Imaging

  • Biopsy

  • Others

• End-use Indication Outlook (Revenue, USD Million, 2018 - 2030)

  • Hospital Laboratories

  • Cancer Diagnostic Centers

  • Research Institutes

  • Others

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany

    • Spain

    • France

    • Italy

    • Denmark

    • Norway

    • Sweden

  • Asia Pacific

    • Japan

    • China

    • India

    • South Korea

    • Australia

    • Thailand

  • Latin America

    • Brazil

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait